private placement

Michelin repurchased 223,572 shares at €29.27 average price in March 2026 for €6.55 million, targeting share annulation via three financial intermediaries.

Ovid Therapeutics surges 18% after Phase 1 data shows OV329 epilepsy drug eliminated safety concerns. Company secures $60M to fund Phase 2 trials.

Metals Acquisition Corp. II closes $230M IPO with 23M units on NYSE under $MTAL.U, including full underwriter over-allotment exercise and $7.6M warrant placement.

Relmada Therapeutics to report Q4 2025 results March 19, 2026, following $160M oversubscribed fundraise and Leerink Partners conference presentation.

Oil stocks $TPET and $BATL surge 13.5% and 10.4% after-hours on Middle East tensions threatening crude supplies. Battalion Oil announces Texas land acquisition and capital raise.

First Atlantic Nickel closes $1.3M financing for Pipestone XL nickel-cobalt project in Newfoundland; also gains 20% interest in Core Critical Metals' British Columbia copper project.

Aureus Greenway (AGH) closes $9M private placement, issuing 3M shares at $3/share to fund working capital and proposed Autonomous Power Corporation merger.

Minerva Neurosciences reported $293.4M FY2025 net loss, largely from non-cash charges. The biotech secured $80M funding and plans Phase 3 roluperidone trial launch in Q2 2026.

Quantum BioPharma raises capital through convertible debentures and debt-to-equity conversion to strengthen balance sheet and fund business development.

First Atlantic Nickel closes $3.9M final funding round at $0.18/share, with strategic investor maintaining 9.9% stake to fund nickel exploration projects.

Battalion Oil surges 15.79% after-hours on Iran tensions and announces $15M private placement at $5.50 per share.

Brookfield Asset Management establishes $1 billion commercial paper program to enhance liquidity and strengthen balance sheet through short-term unsecured debt issuance.

$QUBT reports Q4 2025 revenues of $198K, up 219% YoY. Company raised $750M, acquired Luminar Semiconductor for $110M, narrowing net loss significantly.

Avalon GloboCare closed a $9.75M private placement offering, raising $3.25M immediately with potential for $6.5M more through warrant exercises. Proceeds will fund debt reduction and working capital.

Juggernaut Exploration raises C$10M through flow-through private placement to fund exploration of its Big One Gold Project in British Columbia's Golden Triangle.

Avalon GloboCare raises $3.25M with potential $6.5M more through warrants. Funds will repay debt and support operations.

Cycurion postpones shareholder vote on warrant-related stock issuance to March 19 due to insufficient quorum. The vote involves issuing over 3.3M shares from December 2025 private placement.

Thesis Gold raises C$44M from AngloGold Ashanti and Centerra Gold to advance its Lawyers-Ranch gold-silver project in British Columbia.

Brainstorm Cell Therapeutics raised $2M in February through private placement at $0.60/share. Funds support general operations, regulatory work, and Phase 3b trial preparations for ALS therapy NurOwn.

Ideal Power raises $14M through mixed equity financing to accelerate commercialization of its B-TRAN semiconductor technology and expand customer design-ins.